Neervannan Seshadri 4

What Happened

• Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals (TARS), received two equity awards on March 5, 2026: 27,310 derivative (option) shares and 17,161 Restricted Stock Units (RSUs). Both awards were reported as acquired at a $0.00 per-share price (typical for compensation grants) and therefore show $0 total purchase value on the Form 4.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (filed within the required reporting window).
• Transaction code: A = Award/Grant.
• Option award (27,310 shares): 25% vests on March 5, 2027, then 1/48th of the option shares vest each month thereafter for 3 years (per footnote F1).
• RSU award (17,161 RSUs): each RSU equals a contingent right to one common share; vesting in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030 (per footnotes F2 & F3).
• Shares owned after the transaction: not disclosed in the filing.
• No indication of a sale, purchase, or cashless exercise — these are compensation grants, not open-market purchases.

Context

• These grants are compensatory awards tied to service and standard multi-year vesting schedules. They represent potential future issuance of shares as they vest and do not reflect an immediate market purchase or sale by the insider.
• For retail investors: awards are common for executive compensation and do not in themselves signal a near-term buy or sell by the insider.